MS & Immune Disorders

Filter Your Results

 

News

 

Multiple Sclerosis Association of America Kicks Off Understanding Multiple Sclerosis Progression Campaign for Multiple Sclerosis Awareness Month

Thursday, March 01, 2018—For multiple sclerosis (MS) Awareness Month, the Multiple Sclerosis Association of America (MSAA) focuses on their campaign on Understanding MS Progression…

Microglia May Promote Recovery of Motor Neurons in Amyotrophic Lateral Sclerosis

Wednesday, February 21, 2018—In findings published this week in Nature Neuroscience, researchers Krista J. Spiller, Clark R. Restrepo, Tahiyana Khan, and others described creation of a mouse model of amyo…

New Dose of Generic Glatiramer Acetate Injection for Treatment of Relapsing Multiple Sclerosis Approved by Food and Drug Administration

Wednesday, February 14, 2018—Sandoz announced that the Food and Drug Administraion (FDA) had approved a generic form of glatiramer acetate (Glatopa,Sandoz) in injectable form at a dose of 40 mg/mL 3 times…

Post Hoc Clinical Trials Data for Cladribine, An Investigational Oral Multiple Sclerosis Treatment

Thursday, February 01, 2018—EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, announced that new clinical trial data is being released during the Americas Committee for Treatm…

Got a Minute for MS?

Daniel Kantor, MD, FAAN, FANA

January 2018— Multiple sclerosis (MS) may not be the most prevalent of the diagnoses that we treat, and its place as the “most common disabling neurological disease of young adult…

Multiple Sclerosis—The Truth Lies Within Us

Daniel Kantor, MD

November/December 2017—Data presented at the recent ECTRIMS offer fresh insight and potentially new direction into the cause of multiple sclerosis.

ECTRIMS Data Signal Renewed Emphasis on Multiple Sclerosis Disease Progression, Disability

November/December 2017—Data presented at the Seventh Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) -- Americas Committee for Treatment and Research in Multipl…

Discontinuing Disease-Modifying Therapy in Multiple Sclerosis: Should You Have an Exit Strategy?

With Robert Naismith, MD and John Corboy, MD

November/December 2017—Two experts sound off on the implications of indefinite treatment and whether DMTs should be stopped.

 
 

Contact Info

For advertising rates and opportunities:
Wendy Terry
Publisher
217-652-3859
wterry@bmctoday.com

About Practical Neurology

Launched in 2002, Practical Neurology is a publication uniquely dedicated to presenting current approaches to patient management, synthesis of emerging research and data, and analysis of industry news with a goal to facilitate practical application and improved clinical practice for all neurologists. Our straightforward articles give neurologists tools they can immediately put into practice.

 
  • BRYN MAWR COMMUNICATIONS III, LLC